Background: Patients with hypertrophic cardiomyopathy (HCM) were excluded from pivotal trials comparing the efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists. Methods: Our retrospective cohort study using the TriNetX database compared adults with HCM‐atrial fibrillation who initiated DOACs or vitamin K antagonists. The primary outcomes were all‐cause mortality and ischemic stroke/systemic thromboembolism. Secondary outcomes included major bleeding, intracranial hemorrhage, gastrointestinal bleeding, and all‐cause hospitalization. Subgroup analysis was conducted for obstructive HCM. Results: Among 13 143 patients with HCM‐atrial fibrillation (2963 matched pairs). DOAC use was associated with lower all‐cause mortality (hazard ratio [HR], 0.82[ 95% CI, 0.73–0.93]; P <0.001), major bleeding (HR, 0.85 [95% CI, 0.73–0.99]; P =0.03), and intracranial hemorrhage (HR, 0.54 [95% CI, 0.36–0.79]; P =0.001) compared with vitamin K antagonists. No differences were observed in the rates of ischemic stroke (HR, 0.94 [95% CI, 0.73–1.2]; P =0.6) or the composite of stroke or systemic thromboembolism (HR, 0.87 [95% CI, 0.69–1.10]; P =0.25), gastrointestinal bleeding (HR, 0.97 [95% CI, 0.77–1.22]; P =0.82), or all‐cause hospitalizations (HR, 1.07 [95% CI, 0.93–1.07]; P =0.051). In the subgroup with obstructive HCM, DOAC use was associated with a reduced risk of all‐cause mortality (HR, 0.80 [95% CI, 0.66–0.99]; P =0.035) and major bleeding (HR, 0.76 [95% CI, 0.61–0.96]; P =0.02) without stroke or thromboembolic risk reduction (HR, 0.69 [95% CI, 0.47–1.01]; P =0.05). Conclusions: Among patients with HCM‐atrial fibrillation, DOACs were associated with lower mortality and bleeding risk compared with vitamin K antagonists, with no increased risk of stroke or systemic thromboembolism.